Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety evaluation of Shexiang Tongxin dropping pill (centralized hospital monitoring)
ChiCTR2300070706Phase 4Not yet recruiting
- Sponsor
- Guang'anmen Hospital
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Shexiang Tongxin Dropping Pills in cardiac morbidity and coronary arteriosclerosis, sponsored by Guang'anmen Hospital. Primary endpoint: Adverse drug reactions. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
Shexiang Tongxin Dropping Pills
03
Conditions
cardiac morbiditycoronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2300070706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070706.